Content Type: Article

  • Defense Innovation Unit Air Force Solicitation: Opportunities for Renewable Energy and Energy Storage Project Sponsors

    Defense Innovation Unit Air Force Solicitation: Opportunities for Renewable Energy and Energy Storage Project Sponsors

    ARTICLE / CLIENT ALERT

    Defense Innovation Unit Air Force Solicitation: Opportunities for Renewable Energy and Energy Storage Project Sponsors

    March 30, 2023

    Read time: 4 min

    Key takeaways
    Overview

    Large, utility-scale US Department of Defense (DoD) renewable energy projects, which have not been pursued by the DoD for more than six years, may finally be back. The Defense Innovation Unit (DIU) is actively seeking solutions that would allow the US Department of the Air Force to deploy renewable energy systems and accompanying energy-resilient projects (including energy storage projects) quickly and cost-effectively. The Air Force is seeking a large lead sponsor to provide energy solutions that will meet the demand for on-base utility systems that are resilient, carbon-free, efficient and economical. The DIU and Air Force want to work with an entity that can adequately address these demands at an enterprise scale.

    In depth

    Through this solicitation, the Air Force expects interested parties that respond to the solicitation to be able to (1) reduce, if not eliminate, the Air Force’s up-front installation capital investment; (2) minimize the Air Force’s costs over the life of the asset due to predictable financing, operation and maintenance expenses that are equal to or lower than their existing costs; and/or (3) enable partnerships with vetted developers to provide turnkey design, construction, operations, maintenance and system ownership.

    Initial sites for consideration in the solution concepts may include, but are not limited to, Joint Base Andrews and Arnold Air Force Base in Maryland.

    THE AIR FORCE’S DESIRED FEATURES

    The Air Force anticipates that the selected project sponsor will develop a plan that includes a business model with resilient energy solution concepts, a financial pro forma and the proposed rate, terms and conditions for a long-term solution. The solution provider must optimize aspects of project development, construction and management to achieve program goals and eliminate unnecessary costs through innovative financing techniques and structures and technology employed to meet its objectives.

    Notably, the Air Force will show a preference for solutions that are owned and operated by the solution provider, will be executed rapidly (with low to no up-front costs) and minimize the life of asset cost commensurate with the credit strength of the US government. Further, the Air Force will authorize the solution provider with the requisite authority to manage project stakeholder relationships and define project concepts as the Air Force ideally seeks to provide input only where inherently governmental decisions are required by law, such as environmental permitting and leasing.

    What does this mean in practice and what should project sponsors focus on in their proposals? Historically, the DoD has used both its leasing authority and its authority to enter into power purchase agreements to provide essential revenue streams for energy projects. We predict solutions that emphasize power purchase agreements, with elements of both a capacity payment and an energy payment, will be favored over proposals that rely on energy savings (such as energy savings performance contracts). An exemplar of a project that has worked historically is the Fort Hood project, which had an on-site solar energy component, off-site wind and an energy balancing component. Energy storage will now need to come into play.

    If a project sponsor or syndicate completes a prototype that the government deems acceptable, the government may award a sole-source, follow-on production agreement to that investor or group.

    The deadline for submission is April 7, 2023, at 11:59 EDT. The solicitation will be awarded in accordance with the Commercial Solutions Opening process detailed in HQ-S-C, which was posted to Sam.gov in March 2020. Get more information on solicitation and submission.

    McDermott has extensive experience with energy projects and energy storage projects involving the DoD, having been involved in the most significant DoD energy projects constructed to date. Please reach out to Christopher Gladbach with questions about the solicitation.

    Authors

    Christopher Gladbach

    Partner

    Washington, DC

    More insights

  • Federal Jury Returns $43 Million Verdict for Kickback Scheme in Violation of the False Claims Act

    Federal Jury Returns $43 Million Verdict for Kickback Scheme in Violation of the False Claims Act

    ARTICLE / CLIENT ALERT

    Federal Jury Returns $43 Million Verdict for Kickback Scheme in Violation of the False Claims Act

    March 29, 2023

    Read time: 7 min

    Key takeaways
    Overview

    After a rare False Claims Act (FCA) trial—especially one premised on violations of the Anti-Kickback Statute (AKS)—a federal jury in Minnesota returned a $43 million verdict against Precision Lens, a distributor of medical supplies and devices used in eye surgeries, and its owner, both of which were accused of paying kickbacks to physicians. The verdict triggers potential FCA liability exposure of nearly $490 million.

    In depth

    On February 27, 2023, Cameron-Ehlen Group, Inc., doing business as Precision Lens, and its owner (collectively, the defendants) were found by a federal jury in Minnesota to be in violation of the AKS and, in turn, the FCA by paying unlawful kickbacks to physicians to buy and use the products supplied by the defendants in surgeries paid for by Medicare. After the verdict on March 17, the US Department of Justice (DOJ) requested that the court enter judgment, ordering the defendants to pay nearly $490 million in treble damages and related statutory penalties under the FCA. Although the judgment is still pending, counsel for the defendants said their clients plan to appeal to the US Court of Appeals for the Eighth Circuit.

    FCA cases rarely go to trial, largely because of the potential for severe financial consequences given the treble damages and related per-claim penalties under the FCA and federal program exclusion.

    Given the rarity of FCA trials, this case merits a closer review.

    PROCEDURAL HISTORY

    The case’s lengthy procedural posture began nearly a decade ago when the former vice president of Sightpath Medical, Inc., a company that offers mobile eye surgery services, filed a sealed qui tam suit against the defendants, Sightpath and Sightpath’s corporate parent, TLC Vision Corporation. After investigating for four years, the DOJ elected to intervene. In August 2017, the district court lifted the seal.

    Also in August 2017, TLC Vision, Sightpath and Sightpath’s former CEO entered into a FCA settlement agreement with the DOJ in which the defendants agreed to pay more than $12 million to resolve allegations of kickbacks in the form of trips and sham consulting agreements. Sightpath also entered into a five-year corporate integrity agreement with the US Department of Health and Human Services (HHS) Office of Inspector General (OIG).

    Shortly after the DOJ filed its intervenor complaint, the defendants filed a motion to dismiss in March 2018. Although the district court dismissed several alternative claims, it upheld the FCA allegations, which triggered nearly three years of discovery and motions practice.

    After a six-week trial, the jury returned a verdict, finding the defendants liable for causing 64,575 false claims to be submitted to Medicare, resulting in more than $43 million in single damages and almost $490 million in potential treble damages and related statutory penalties.

    SUMMARY OF ARGUMENTS

    The DOJ’s theory in the case was that the defendants’ business model was based on using remuneration to build strong relationships with physician customers who have influence over which products are used in surgeries to induce them to use and purchase the defendants’ products. To accomplish their goal, from January 1, 2006, through December 31, 2015, the DOJ said that the defendants provided kickbacks, both directly and indirectly through Sightpath, in the form of free or discounted luxury trips on private planes, tickets to sporting events, frequent flyer miles and other items of value. For example, the defendants flew several physicians on a private plane to the 2011 Masters Golf Tournament in Augusta, Georgia, and provided them a steak dinner, lodging in a private home and tickets to the tournament. The physicians paid only $500 each for the trip, even though records indicated the flights alone cost tens of thousands of dollars.

    The DOJ alleged that the defendants treated these costs as business expenses and linked them directly to sales by, for example, assessing and keeping track of their value to ensure they were provided to physician customers who could benefit the defendants’ business.

    The defendants allegedly knew their conduct was unlawful because they continued providing kickbacks even after obtaining advice from counsel, reviewing the AdvaMed Code and recent settlements involving kickbacks based on similar conduct, and discussing the need to stop such practices in meetings.

    Further, the defendants allegedly knew and understood the surgeries performed with the defendants’ products were paid for by Medicare, which included the payment of facility fees and professional fees. The surgery claims were presented to Medicare with billing codes as if they were eligible for payment, but without disclosing that the providers connected with the claim were provided unlawful kickbacks to use the defendants’ products in violation of the AKS.

    Therefore, by paying the kickbacks, the defendants knowingly caused the submission of false claims to Medicare, violating the FCA.

    In response to the allegations of AKS violations, the defendants argued that the alleged kickbacks were nothing more than part of a reciprocal social relationship with the physician customers (who were the owner’s close friends or acquittances with common interests) and not intended as an illegal quid pro quo to use the defendants’ products. The defendants also argued that the meals and private flights were standard business practices permissible under industry guidance because they were related to legitimate business purposes, such as evaluation or training on their products. Further, the amounts charged were reasonable and within range of fair market value.

    The defendants also argued that most of the physician customers used the defendants’ products for years before the alleged kickbacks because they either preferred the products—the defendants happened to be the exclusive distributor in the region—or simply used the products because they were required to do so by their respective surgery facilities. The defendants cited long-term data to argue that there was no correlation between the alleged kickbacks and utilization of the defendants’ products by the physician customers.

    With respect to the FCA allegations, the defendants argued that the OIG and the Centers for Medicare & Medicaid Services (CMS) were made aware of the alleged kickbacks in 2010 and determined that they were not an issue after investigating. The defendants also argued that Medicare continued to reimburse the claims and paid no additional cost than it otherwise would have for the surgeries if other products were used. Therefore, the DOJ could not prove that the defendants caused the submission of false claims, that the alleged kickbacks were material to payment or that the government suffered any damages.

    PRACTICAL IMPLICATIONS AND KEY TAKEAWAYS

    This case shows the government’s sustained focus and scrutiny with respect to medical product company marketing practices. For at least the past 20 years, there have been many FCA settlements with manufacturers over marketing practices, including travel, gifts and entertainment. However, there hasn’t been many trials. Given the FCA liability exposure, companies should carefully review their compliance policies and procedures to ensure that their marketing practices—especially marketing practices involving hospitality, meals and entertainment—include the proper controls to ensure they are mitigating risk under the fraud and abuse laws.

    Authors

    Tony Maida

    Partner

    New York – One Vanderbilt Avenue

    More insights

  • New Cosmetics Regulatory Scheme to Reshape Industry’s Relationship with FDA

    New Cosmetics Regulatory Scheme to Reshape Industry’s Relationship with FDA

    ARTICLE / CLIENT ALERT

    New Cosmetics Regulatory Scheme to Reshape Industry’s Relationship with FDA

    March 2023

    Read time: 5 min

    Key takeaways
    Overview

    The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) went into effect with US President Joe Biden’s signing of the Consolidated Appropriations Act, 2023. This legislation will profoundly change the way cosmetic companies interact with the US Food & Drug Administration (FDA). Before MoCRA was signed into law, there had been no major updates to the FDA’s regulation of cosmetics in nearly 50 years and only limited oversight of these products. As the FDA begins its rulemaking process, the cosmetic industry should actively participate in the development of regulations to ensure that they reflect practical considerations and reasonable requirements. Stakeholders should also raise specific issues during the rulemaking process to allow the FDA to clarify any potential confusion involving the regulations.

    VIEW OUR INFOGRAPHIC FOR DEADLINES, KEY DECISIONS AND MORE

    In depth

    Under MoCRA, cosmetic companies are required to register, list products, comply with good manufacturing practices (GMPs), develop safety data, include a domestic address and contact information on the product label, label allergens, include a professional use label for applicable products, maintain records and report adverse events.

    Although there are many aspects of MoCRA that should be considered, manufacturers should keep in mind, for example, that the definition of a “serious adverse event” for combination over-the-counter drug and cosmetic products (e.g., tinted moisturizers with sunscreen) under MoCRA differs from the definition for nonprescription drugs:

    • “Serious adverse event” for nonprescription drugs is defined as “an adverse event that (A) results in (1) death; (2) a life-threatening experience; (3) inpatient hospitalization; (4) a persistent or significant disability or incapacity; or (5) a congenital anomaly or birth defect; or (B) requires, based on reasonable medical judgment, a medical or surgical intervention to prevent an outcome described under subparagraph (A).” (See 21 U.S.C.A. § 379aa.)
    • “Serious adverse event” for cosmetic products is defined as “an adverse event that (A) results in (1) death; (2) a life-threatening experience; (3) inpatient hospitalization; (4) a persistent or significant disability or incapacity; (5) a congenital anomaly or birth defect; (6) an infection; or (7) significant disfigurement (including serious and persistent rashes, second- or third-degree burns, significant hair loss or persistent or significant alteration of appearance), other than as intended, under conditions of use that are customary or usual; or (B) requires, based on reasonable medical judgment, a medical or surgical intervention to prevent an outcome described in subparagraph (A).” (See MoCRA.)

    MoCRA also granted the FDA greater authority to enforce against cosmetic companies. The FDA may inspect facilities, access certain records, request voluntary recalls and order mandatory recalls. If there is reasonable probability that a product will cause serious adverse health consequences or death to humans, MoCRA allows the FDA to suspend a facility’s registration, an action that may be combined with other already existing enforcement tools.

    These new regulatory requirements will significantly change the cosmetic industry’s relationship with the FDA, as interactions and oversight will drastically increase.

    NEXT STEPS

    The regulatory landscape is seismically shifting for the cosmetic industry. As the FDA engages stakeholders and initiates rulemaking, companies should consider engaging in the process to ensure that regulatory requirements accurately reflect current practices and consumers’ use of cosmetic products. With quickly approaching deadlines, the FDA must develop infrastructure to allow companies to comply with registration and product listing, as well as more complex requirements such as adverse event reporting and GMPs.

    As an initial first step, companies should consider an internal assessment of existing products and compliance with the proposed requirements under MoCRA. The first MoCRA-related deadline is December 2023, when companies must register their facilities, include professional use labels where applicable, and submit a cosmetic product listing and adverse event reporting to the FDA. Although registration and listing will be primarily administerial, companies should develop standard operating procedures to manage the process, as well as monitor adverse events and report serious ones by qualified individuals. Companies should also be prepared to address additional MoCRA-required activities, such as identification of allergens, allergen labeling and GMPs, as the FDA engages in rulemaking on those issues.

    The McDermott team is closely monitoring the MoCRA rulemaking process and will release updates as more information becomes available from the FDA. For assistance with MoCRA compliance or submitting comments, please contact the author of this On the Subject.

    Authors
    More insights

  • Washington State Capital Gains Tax Upheld; Payments Due April 18

    Washington State Capital Gains Tax Upheld; Payments Due April 18

    ARTICLE / CLIENT ALERT

    Washington State Capital Gains Tax Upheld; Payments Due April 18

    March 28, 2023

    Read time: 3 min

    Key takeaways
    Overview

    The amount of taxes due this year for many Washington state taxpayers just increased following a 7-2 decision from the Washington Supreme Court in which it reversed a lower court’s ruling and held that the state’s new capital gains tax is valid. Quinn v. State, No. 100769-8 (Wash. Supreme Ct. Mar. 24, 2023).

    The primary issue was whether the state’s capital gains tax, which was enacted in 2021, should be classified as an “income tax” or an “excise tax.” Although the Internal Revenue Service and all 41 states that tax capital gains treat such gains as income and a tax on them as an income tax, the Evergreen State has its own rules when it comes to defining basic terminology for purposes of taxation. For example, the state’s Constitution defines the word “property” so broadly that the courts have interpreted that term to include income. Thus, any proposed “income tax” is subject to the same uniformity and levy requirements placed on the state’s property taxes.

    In finding that the new capital gains tax is an excise tax, the Washington Supreme Court disregarded the actual language in the statute (which states that “[t]he tax applies when the Washington capital gains are recognized by the taxpayer in accordance with this chapter”) and instead focused on the sale or exchange of capital assets, not the gains themselves. In other words, the Court held that the taxable incident of the tax is the transaction, not the income.

    The dissent points to this flaw in the majority’s reasoning and explains that since the capital gains tax is on net income, the number of underlying transactions is irrelevant. An individual with multiple transactions and no gain could escape the tax, while an individual that had just one transaction with a net income over $250,000 would have to pay. Thus, the dissent fairly argues that the realization of profit is the taxable incident, not the transfer itself.

    Unfortunately, dissenting opinions carry little weight when determining the validity of the tax at issue in any given case. Individuals with capital gains over $250,000 are now subject to a 7% tax in Washington state and are required to file a capital gains tax return along with a copy of their federal income tax return for the same taxable year. For capital gains made in 2022, the return is due on April 18, 2023.

    The capital gains tax only applies to gains allocated to Washington state, and there are several exemptions, deductions and credits available. If you have questions about the Washington state capital gains tax, please contact Troy Van Dongen.

    In depth
    Authors

    Troy M. Van Dongen

    Partner

    San Francisco

    More insights

  • Preparing for the End of the COVID-19 Emergency: Mental Health Parity Financial Requirements and Quantitative Treatment Limitations; Employee Assistance Plans

    Preparing for the End of the COVID-19 Emergency: Mental Health Parity Financial Requirements and Quantitative Treatment Limitations; Employee Assistance Plans

    ARTICLE / CLIENT ALERT

    Preparing for the End of the COVID-19 Emergency: Mental Health Parity Financial Requirements and Quantitative Treatment Limitations; Employee Assistance Plans

    March 28, 2023

    Read time: 5 min

    Key takeaways
    Overview

    Our April 3, 2023, webinar explored the impacts that the end of the PHE and NE will have on employee benefit plans and what actions employers and benefit plan sponsors should be taking to prepare. Watch the “How Employers Should Prepare for the End of the Covid-19 National and Public Health Emergencies” webinar recording to learn more.


    The Biden administration has announced its intention to end the COVID-19 National Emergency (NE) and the COVID-19 Public Health Emergency (PHE) on May 11, 2023 (read our series introduction for more information). Among other things:

    • The NE and the PHE modified the rules governing financial requirements and quantitative treatment limitations under the Mental Health Parity and Addiction Equity Act (MHPAEA). The end of the NE and the PHE will require modifications to group health plans’ and health insurance issuers MHPAEA testing as it relates to financial requirements and quantitative treatment limits. The NE and the PHE also affect the design and operation of some employee assistance plans (EAPs).
    • The NE and the PHE allowed plan sponsors to expand coverage under excepted benefit EAPs in certain respects without risking their status as the Health Insurance Portability and Accountability Act (HIPAA)-excepted benefits.
    In depth

    MHPAEA 

    MHPAEA requires that the financial requirements (such as coinsurance and copays) and quantitative treatment limits (such as visit limits) imposed on mental health or substance use disorder (MH/SUD) benefits cannot be more restrictive than the predominant financial requirements and treatment limitations that apply to substantially all medical/surgical benefits in a particular benefit classification. During the public health emergency period, group health plans and health insurance issuers were permitted to disregard certain items and services related to testing for the detection of SARS-CoV-2, the virus that causes COVID-19, when performing the “substantially all” and “predominant” tests. Absent this relief, the costs of covering COVID-19 testing items and services without cost-sharing would be the amounts allocated to medical/surgical benefits, thereby putting group health plans and health insurance issuers at risk of running afoul of MHPAEA quantitative treatment limits.

    From and after the end of the PHE, group health plans and health insurance issuers must include the cost of covering COVID-19 tests, either diagnostic or over-the-counter, or testing-related services, when calculating MHPAEA quantitative treatment limits.

    Action Items: Employers should revisit their MHPAEA compliance testing to ensure that the coverage of COVID-19 tests is properly accounted for in applying the relevant quantitative treatment limits. There is, however, no longer a requirement that a group health plan or health insurance issuer cover these services without charge.

    EMPLOYEE ASSISTANCE PLANS

    The end of the NE and the PHE could have various impacts on EAPs depending on the specific plan design. Employers may, for example, see a spike in the need for mental health support that could be met through EAP services. While the pandemic may be winding down, the mental health impacts of the past three years may continue for many employees. Employers may need to continue to offer mental health services and resources through their EAPs, and potentially explore expanding mental health services through an EAP or otherwise, to support employees who are struggling with anxiety, depression or other mental health issues related to the pandemic.

    Particular attention is required in the case of excepted benefit EAPs. Excepted benefit EAPs do not provide minimum essential coverage for Affordable Care Act (ACA) purposes. This means that coverage under an excepted benefit EAP does not disqualify a participant from qualifying for a premium tax credit from an ACA state healthcare exchange. To qualify as an excepted benefit EAP, an EAP must not provide benefits that are significant in the nature of medical care. During the NE and the PHE, the tri-agencies (US Departments of Labor, Health and Human Services, and Treasury)  clarified that an excepted benefit EAP will not be considered to provide benefits that are significant in the nature of medical care solely because it offers benefits for diagnosis and testing for COVID-19 while a public health emergency declaration or a national emergency declaration is in effect.

    Action Items: Plan sponsors should evaluate their EAPs to determine whether any benefits added to provide coverage for COVID-19 diagnosis and testing must now be removed from the EAP as a result of the end of the NE and PHE.  More broadly, it will also be important for employers to stay attuned to the changing needs of their employees and consider any adjustments to their EAP offerings as the pandemic continues to evolve.

    For any questions regarding the end of the PHE and/or NE, please contact your regular McDermott lawyer or one of the authors.

    Authors

    Jacob M. Mattinson

    Partner

    Chicago

    Sarah G. Raaii

    Partner

    Chicago

    More insights

  • IRS Releases Notice on the Taxation of NFTs as Collectibles

    IRS Releases Notice on the Taxation of NFTs as Collectibles

    ARTICLE / CLIENT ALERT

    IRS Releases Notice on the Taxation of NFTs as Collectibles

    March 27, 2023

    Read time: 6 min

    Key takeaways
    Overview

    In its first published guidance addressing non-fungible tokens (NFTs), the Internal Revenue Service (IRS) released Notice 2023-27 on March 21, 2023, announcing its intent to issue guidance related to the taxation of certain NFTs as “collectibles.”

    The characterization of an NFT as a collectible is significant as it influences (1) whether the gain from the sale of an NFT is taxed at the maximum long-term (federal) capital gains rate of 28% versus a more desirable maximum long-term capital gains rate for assets that are not collectibles and (2) whether the transfer of an NFT to an individual retirement account (IRA) results in a distribution from the IRA to the account holder.

    In depth

    TAXATION OF COLLECTIBLES GENERALLY

    Generally, capital assets that have been held for more than one year are subject to favorable tax rates, which depending on the taxpayer’s tax profile, may be equal to either 0%, 15% or 20%. However, if the capital gain relates to a collectible item, the maximum long-term capital gains rate is 28%. For this purpose, collectibles generally include any work of art, rug or antique, metal (except certain coins), gem, stamp, coin, alcoholic beverage (e.g., vintage wines), musical instrument, historical object (e.g., a document or clothes) or other tangible personal property items that the IRS determines is a collectible.

    Additionally, an IRA that purchases a collectible is treated as having made a distribution in an amount equal to the cost of the collectible (i.e., the fair market value at the time of acquisition) to the IRA account holder. Such a constructive distribution is taxable and subject to the 10% additional tax on distributions to the IRA account holder before age 59 and a half. Upon actual distribution of the collectible from the IRA to the account holder, the amount of the constructive distribution is not included in income but any fair market value exceeding that amount would be taxable. Appreciation in the collectible’s value is tax-deferred within the IRA until distribution.

    NFTS AS COLLECTIBLES

    NFTs

    The Notice defines an NFT as a unique digital identifier that is recorded using distributed ledger technology and which may be used to certify authenticity and ownership of an associated right or asset. Ownership of an NFT may provide the holder a right with respect to a digital file that is typically separate from the NFT. These rights may also relate to other types of assets, such as a right to attend a ticketed event or certification on the ownership of physical assets. Sometimes ownership denotes rights to multiple assets, such as artwork and club membership.

    Look-Through Rule

    The IRS intends to issue guidance that determines whether an NFT constitutes as a collectible for US federal income tax purposes by looking directly through the NFT to the underlying associated right or asset and determining whether such associated right or asset is a collectible under existing guidance. For example, an NFT that certifies ownership of a gem constitutes a collectible. Similarly, if the underlying associated right or asset is not a collectible under existing guidance, the NFT does not constitute a collectible. For example, a right to use or develop a “plot of land” in a virtual environment generally is not a collectible and, therefore, an NFT that provides a right to use or develop the “plot of land” in the virtual environment generally does not constitute a collectible.

    The IRS is also considering whether the underlying associated right or asset of an NFT (such as a digital file that contains an image) is considered a “work of art” in which case, the NFT would be a collectible under existing guidance.

    CONCLUSION

    As the first piece of published guidance addressing NFTs, the Notice shows the importance of the IRS to address issues in an area where taxpayers have historically been operating with little or no guidance. NFTs came into existence around 2014 and have achieved mainstream attention beginning in 2020, with the price of at least one NFT reaching approximately $91.8 million.

    While the Notice may imply that under the look-through rule, if the underlying associated right or asset is not a collectible, proceeds from the sale of such NFT will be subject to a maximum 20% long-term capital gains tax rate, the existence of the look-through rule creates additional questions that taxpayers may need to consider, such as:

    • Does the look-through rule only apply to whether an NFT is treated as a collectible, or will it be more broadly applied?
    • Under the look-through analysis, if an NFT provides its holder the right to legal ownership of stock or a partnership interest, is withholding required under existing applicable law (e.g., backup withholding or withholding under Sections 1445 or 1446(f) of the Internal Revenue Code of 1986, as amended)?
    • If the underlying asset is inventory used in the transferor of an NFT’s trade or business, is the sale of the NFT subject to taxation at ordinary income tax rates?
    • Is the associated right of an NFT a right to passive income? How is such income sourced or taxed?

    The creativity of varying uses of NFTs continues to expand, including one online user uploading a video of utilizing an NFT to act as a car key. Other use cases could include NFTs that store records, act as tickets to entertainment events or transfer land deeds.

    The Notice does not address all tax issues related to NFTs (such as the ones identified above), and specifically requests comments from taxpayers on the definition of an NFT, the look-through analysis and if there are any other key issues the IRS should consider with respect to taxation of NFTs.

    If the Notice’s approach is adopted, NFT holders and tax professionals will need to conduct a look-through analysis of the rights and assets associated with NFTs. Given the evolving nature of NFTs and their associated rights and underlying assets, this analysis will not be a simple one.

    If you have questions about the tax implications of NFTs, please contact the authors of this article or your regular McDermott lawyer.

    Authors

    John T. Lutz

    Partner

    New York – One Vanderbilt Avenue

    Andrew M. Granek

    Partner

    New York – One Vanderbilt Avenue

    More insights

  • Healthcare Regulatory Check-up | February 2023

    Healthcare Regulatory Check-up | February 2023

    ARTICLE / REPORT

    Healthcare Regulatory Check-up | February 2023

    March 2023

    Read time: 2 min

    Overview

    This issue of McDermott’s Healthcare Regulatory Check-Up highlights significant regulatory activity for February 2023. We discuss several criminal and civil enforcement actions that involve Anti-Kickback Statute (AKS) and beneficiary inducement issues. We also highlight the recent Office of Inspector General (OIG) advisory opinions 23-01 and 23-02, as well as other notable developments, including the US Department of Justice (DOJ) False Claims Act (FCA) Report for FY 2022.

    In depth
    Tabs

    Emily Jane Cook

    Partner

    Los Angeles, Washington, DC

    Tony Maida

    Partner

    New York – One Vanderbilt Avenue

    Monica Wallace

    Partner

    Chicago

    Nicholas F. Alarif

    Partner

    Washington, DC

    More insights
    Endnotes

  • Health Annual Report 2023 | Physician Practice Management 2022 Year in Review

    Health Annual Report 2023 | Physician Practice Management 2022 Year in Review

    ARTICLE / REPORT

    Health Annual Report 2023 | Physician Practice Management 2022 Year in Review

    March 2023

    Read time: 2 min

    Overview

    The physician practice management (PPM) sector is expected to continue its rapid growth in 2023, with new PPMs emerging to seize opportunities in cardiology, orthopedics, ophthalmology, urology, gastroenterology, primary care, women’s health and other specialties. However, a tight labor market, wage inflation and fixed reimbursement pose challenges to all areas of healthcare, including the PPM sector. Additionally, new proposed rules governing physician transactions and employment agreements have the potential to fundamentally alter the PPM industry. Our PPM team shares their insights on significant 2022 developments and takes a strategic look ahead at regulatory and transactional issues that will shape business outcomes in 2023, including:

    • Physician alignment
    • Provider employer agreements
    • Regulatory areas to watch to reduce risk
    • Hot specialties drawing investor attention
    In depth
    Tabs

    Dana Dombey

    Partner

    Miami

    Larry C. Guess

    Partner

    Chicago

    Amanda Jester

    Partner

    Austin

    Joseph M. Parise

    Partner

    Boston

    Joel C. Rush

    Partner

    Washington, DC

    Ashley M. Fischer

    Partner

    Chicago

    Jamie B. Gelfman

    Partner

    Miami

    Steven J. Schnelle

    Partner

    New York – One Vanderbilt Avenue

    More insights
    Endnotes

  • Illinois’ New Paid Leave Law: What Employers Need to Know

    Illinois’ New Paid Leave Law: What Employers Need to Know

    ARTICLE / CLIENT ALERT

    Illinois’ New Paid Leave Law: What Employers Need to Know

    March 22, 2023

    Read time: 7 min

    Key takeaways
    Overview

    On March 13, 2023, Illinois Governor J.B. Pritzker signed the Paid Leave for All Workers Act (PLAWA) into law, guaranteeing all workers in the state of Illinois 40 hours of paid time off each year for any reason. The law goes into effect on January 1, 2024, so employers need to use the remaining months of 2023 to ensure they are prepared for compliance with the new law.

    Illinois is now the third state to enact such a law, following Maine and Nevada.

    In depth

    PLAWA COVERAGE

    PLAWA has broad coverage, applying to all employers that have at least one employee in the state of Illinois. There are limited exceptions: i.e., employees in the construction and parcel delivery industry covered by a collective bargaining agreement are excluded from coverage. PLAWA also does not apply to independent contractors.

    There is an issue of coordinating PLAWA with existing paid leave provisions under local law for employees in Chicago or elsewhere in Cook County. PLAWA excludes “any employer that is covered by a municipal or county ordinance…that requires employers to give any form of paid leave to their employees, including paid sick leave or paid leave.”

    Since Chicago and Cook County already have ordinances ensuring paid sick leave for certain employees, compliance with those ordinances may satisfy employers’ obligations under PLAWA. Interestingly, the plain meaning of this language excludes employers who have any employees covered by the Chicago or Cook County paid leave mandates from compliance not only for its employees in those locations but also for its employees located elsewhere in the state.

    Note that if the employer is located in one of the 100-plus municipalities in Cook County that have opted out of the paid leave ordinance, this exemption likely would not apply. Employers should confirm whether they are in fact covered by the Cook County ordinance before relying on the exemption from PLAWA.

    USING PLAWA LEAVE

    Employees will start accruing paid leave on PLAWA’s effective date: January 1, 2024. However, employees cannot use accrued paid leave until 90 days after PLAWA’s effective date or the date they begin working, whichever is later. Thus, employers must be prepared to respond to requests for PLAWA leave starting on March 31, 2024.

    Employees can use PLAWA leave for any purpose whatsoever and have no obligation to disclose a reason to their employer. Foreseeable leave requires at least seven days’ notice. Unforeseeable leave requires notice as soon as practicable. Those are the same requirements for notice under the federal Family and Medical Leave Act (FMLA).

    Employers can set limits on the minimum amount of leave an employee can use per day, but they must not make the limit higher than two hours per day. And employers may set policies and procedures on how employees should give notice of their intent to take any PLAWA leave.

    PLAWA ACCRUAL

    Hourly employees will accrue one hour of paid leave under PLAWA for every 40 hours worked, up to a maximum of 40 hours of paid leave per year. For purposes of PLAWA accrual, overtime-exempt employees are treated as working 40 hours each workweek “unless their regular workweek is less than 40 hours.”

    In lieu of accrual by hours worked, employers can choose to frontload the entire 40 hours of paid leave to their employees annually. The employer should notify its employees in writing of its chosen accrual method and of any future changes in the accrual method.

    The employer’s choice of accrual method (frontload versus hourly accrual) affects how unused hours carry over from year to year. With frontloaded accrual, unused leave expires at the end of the year; with hourly accrual, employers must allow up to 40 hours of paid leave to “roll over” annually. Regardless of the accrual method, employers may limit employees to using only 40 hours of leave per year.

    Employers are not required to pay out any unused leave accrued under PLAWA unless “it is credited to an employee’s paid time off bank or employee vacation account.” Such integration requires PLAWA leave to be paid out on termination. Employers should be careful when integrating PLAWA leave into a paid time off bank in this way, as it raises additional operational issues in accounting for which time is PLAWA-time and must be available for use under PLAWA’s terms.

    PLAWA ENFORCEMENT

    There is no private right of action under PLAWA. As a result, individual employees cannot sue their employers for noncompliance. Instead, employees will need to file a complaint with the Illinois Department of Labor, which has statutory authority to pursue remedies on the employee’s behalf.

    PLAWA also has an anti-retaliation provision prohibiting employers from retaliating against employees for taking leave or otherwise interfering with the employee’s rights under the Act. This is likewise enforced by the Illinois Department of Labor. Violations of PLAWA will expose employers to civil penalties of up to $2,500 for each offense in addition to other remedies. Unlike the Illinois Wage Payment and Collection Act, there is no individual officer liability under PLAWA for any violations of the statute.

    BEST PRACTICES FOR PLAWA COMPLIANCE

    Employers will need to revisit their leave policies. If employers already provide at least 40 hours of paid leave per year that can be taken for any reason, no change in policy is required. If not, employers will need to revise their policies for compliance with PLAWA. Key considerations will include:

    A. Choosing how to handle the differences between PLAWA and the Chicago and Cook County paid leave mandates with [1] separate paid leave policies for employees subject to Chicago and Cook County paid leave mandates and those subject to PLAWA elsewhere; [2] a single policy that applies the highest common denominator to all employees; or [3] a policy that assumes that the plain meaning of PLAWA holds up in court and thus eliminates the need for applying PLAWA at all for employers with any employees in either Chicago or suburban Cook County;

    B. Choosing whether to keep PLAWA leave separate from other paid time off banks to avoid the obligation to pay out PLAWA on termination of employment, or to integrate PLAWA into a regular time off bank to reduce the burden of administering multiple paid leave accounts; and

    C. Choosing how to write coherent policies and procedures that maximize understanding of the paid and unpaid leave options (and the discrete requirements for each) and minimize the risk of misadministration of state and local paid leave benefits.

    Employers must also provide written notice of PLAWA’s requirements in their employee handbook and ensure that all records of paid leave accrued and taken by employees are retained for at least three years. There will also be notice posting required when the Department of Labor fulfills its obligation to draft such a poster.

    For any questions regarding the Act, please contact your regular McDermott lawyer or one of the authors of this article.

    Authors

    Brian Mead

    Partner

    Chicago

    More insights

  • CMS Extends Timeline of Section 111 Civil Monetary Penalties Final Rule

    CMS Extends Timeline of Section 111 Civil Monetary Penalties Final Rule

    ARTICLE / CLIENT ALERT

    CMS Extends Timeline of Section 111 Civil Monetary Penalties Final Rule

    March 22, 2023

    Read time: 4 min

    Key takeaways
    Overview

    On February 18, 2023, the Centers for Medicare and Medicaid Services (CMS) extended the timeline for publishing the Medicare Secondary Payer and Certain Civil Monetary Penalties final rule by one additional year, stating that it experienced “delays related to the need for additional, time-consuming data analysis.”

    In depth

    The Medicare Secondary Payer Act (MSPA), enacted in 1980, made Medicare a secondary payor to certain primary plans and created a statutory duty for liability insurers and self-insured entities to pay for Medicare beneficiaries’ healthcare services, where applicable, when Medicare is not the beneficiary’s primary health insurer. Along with the MSPA, Section 111 of the Medicare, Medicaid and SCHIP Extension Act of 2007 (MMSEA) added mandatory reporting requirements with respect to Medicare beneficiaries who have coverage under group health plan arrangements and Medicare beneficiaries who receive settlements, judgments, awards or other payment from liability insurance (including self-insurance), no-fault insurance or workers’ compensation, collectively referred to as non-group health plans. Section 111 also added provisions that allow CMS to impose civil monetary penalties against non-group health plans responsible reporting entities. Responsible reporting entities generally include non-group health plans and other insurers.

    On February 18, 2020, CMS issued a proposed rule implementing civil monetary penalties for noncompliance with the MMSEA Section 111 reporting requirements. CMS was expected to complete and release its final rule within the standard three-year period for release, which ended in February 2023. However, on February 18, 2023, CMS extended the timeline for publishing the final rule by one additional year. CMS explained that it was unable to complete the time-consuming data analysis resulting from public inquiry because the public listening sessions raised additional concerns that required additional research prior to publishing a final rule. CMS would like to critically consider the economic impact of the proposed rule across different insurer types. CMS also noted that its focus on the COVID-19 public health emergency contributed to the delay in finalizing the proposed rule.

    In the same vein, CMS withdrew a notice of proposed rulemaking related to the MSPA in October 2022. The proposed rule was expected to provide guidance on liability and obligations associated with future medical costs and Medicare Set-Asides (MSAs), including liability and no-fault MSAs. The notice of proposed rulemaking was initially announced in 2018, subsequently updated and later withdrawn. Given the complexities of liability/no-fault claims, many insurers anticipated CMS’s guidance on such MSA matters.

    Takeaway

    Despite the delayed rulemaking, there is no indication that the underlying civil monetary penalty statutory provisions will be amended. Therefore, civil monetary penalty final rules are anticipated in the future. Plans and responsible reporting entities should continue to implement systems and plans for compliance. CMS also continues to provide guidance on different components of the MSPA, including workers’ compensation MSAs; recovery thresholds for certain liability insurance; no-fault insurance; and workers’ compensation settlements, judgments, awards and other payments. Companies with reporting obligations should seek counsel on how to best meet the reporting guidelines and avoid potential future CMS liabilities.

    Authors

    Emily Jane Cook

    Partner

    Los Angeles, Washington, DC

    More insights